When should ponatinib be started in a patient with chronic myeloid leukemia (CML) blast crisis progressing to acute myeloid leukemia (AML) who is undergoing high‑dose cytarabine (HiDAC) chemotherapy?

Timing of Ponatinib in CML Blast Crisis to AML with HiDAC Chemotherapy

Ponatinib should be initiated concurrently with HiDAC chemotherapy from day 1 of induction, continuing through the chemotherapy cycle at a starting dose of 30-45 mg daily, with dose adjustments based on blood count recovery and response. 1

Rationale for Concurrent Administration

The MATCHPOINT trial provides the strongest evidence for this approach, demonstrating that ponatinib combined with intensive chemotherapy (FLAG-IDA, which includes high-dose cytarabine) from day 1 achieved a 69% second chronic phase rate after one cycle in blast phase CML patients 1. This concurrent strategy is critical because:

• Immediate BCR::ABL1 inhibition is essential when blast crisis has transformed to AML, as the underlying CML clone drives disease progression
• Delaying TKI therapy allows resistant clones to proliferate during chemotherapy-induced cytopenia
• The combination showed 71% of patients successfully bridged to allogeneic transplant 1

Specific Dosing Algorithm

Starting dose selection:

• 45 mg daily if BCR::ABL1 transcript level >10% or T315I mutation present 2
• 30 mg daily for other scenarios, which was the optimal dose identified in MATCHPOINT 1
• Administer from day 1 through day 28 of the chemotherapy cycle 1

Dose modifications during chemotherapy:

When cytopenia develops (which is expected with HiDAC):

1. First episode of ANC <0.5 × 10⁹/L: Hold ponatinib until ANC ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L, then resume at same dose 3

2. Determine if cytopenia is disease-related or treatment-related through bone marrow examination 3

   • If disease-related (leukemia): Continue ponatinib at same dose or consider dose escalation
   • If treatment-related: Follow the hold-and-resume algorithm above

3. Second episode: Hold until count recovery, resume at 45 mg daily 3

4. Third episode: Hold until count recovery, resume at 30 mg daily 3

5. Subsequent episodes: Further reduce to 15 mg daily 3

Critical Management Considerations

Cardiovascular monitoring is paramount given ponatinib's arterial occlusive event (AOE) risk:

• Baseline cardiovascular assessment before starting ponatinib
• The MATCHPOINT trial reported 25% dose-limiting toxicities, including cardiomyopathy and cerebral venous sinus thrombosis 1
• Older age, hypertension, diabetes, hypercholesterolemia significantly increase AOE risk 4, 5
• Consider starting at 30 mg rather than 45 mg in patients with cardiovascular risk factors

Do NOT delay ponatinib until after chemotherapy completion - this approach lacks evidence and allows disease progression during the critical induction period. The concurrent strategy from MATCHPOINT represents the highest-quality evidence for blast phase CML management 1.

Transition to post-remission therapy:

• Once second chronic phase is achieved, continue ponatinib through consolidation
• Dose reduction to 15-30 mg daily may be appropriate once deep molecular response (MR4.0 or better) is achieved 6
• The goal is bridging to allogeneic stem cell transplantation, which remains the only curative option for blast crisis 1, 7

Common pitfall to avoid: Withholding ponatinib during expected chemotherapy-induced cytopenias. The evidence shows ponatinib should be held only when counts drop below specified thresholds, then promptly resumed upon recovery 3. Prolonged interruptions compromise the ability to achieve second chronic phase and successful transplant bridging.